- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01447784
ToleroMune House Dust Mites (HDM) Exposure Chamber Study
A Double-blind, Randomised, Placebo-controlled Study to Evaluate Three Doses of ToleroMune HDM in House Dust Mite Allergic Subjects Following Challenge With House Dust Mite Allergen in an Environmental Exposure Chamber.
House Dust Mites (HDM) are arachnids that infest bedding, carpet, upholstered furniture and fabric. Like many other allergens, exposure to HDM allergens in sensitised patients is associated with poorer lung function, greater medication requirements and more asthma symptoms as well as chronic rhinosinusitis symptoms. In contrast to other allergens, there is evidence that HDMA leads to the development of asthma, in addition to exacerbating pre-existing asthma in HDM-sensitised patients.
ToleroMune HDM is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of HDM allergy
This study will look at the efficacy, safety and tolerability of three doses of ToleroMune HDM in HDM allergic subjects following challenge with HDM allergen in an Environmental Exposure Chamber (EEC)).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is designed as a randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability of ToleroMune HDM in HDM allergic subjects with allergic rhinoconjunctivitis. The efficacy of ToleroMune Ragweed will be explored in subjects using an EEC.
The study will consist of 3 study periods. In Period 1, Screening will be performed up to a maximum of 16 weeks before randomisation and may consist of one or two visits to the clinic, at the Investigator's discretion. Baseline Challenge will consist of 3 visits to the EEC. Eligible subjects will complete a daily diary card at home for two weeks following the final visit to the EEC.
In Period 2, subjects in each cohort complying with the inclusion/exclusion criteria will be randomised to one of four groups and will receive treatment over 11 visits in 3 dosing periods for each subject. Within each dosing period visits will take place at intervals of 4 weeks (28±2 days). There will also be two EEC visits during the treatment period and one post treatment EEC visit. Following the final visit to the EEC, subjects will complete a daily diary card at home for two weeks.
In Period 3, Follow-up will be conducted 16-21 days after the final EEC visit.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Mississauga, Ontario, Canada, L4W 1N2
- Cetero Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Male or female, aged 18-65 years.
- Minimum 1-year documented history of rhinoconjunctivitis on exposure to HDM.
- Positive skin prick test to Der p allergen.
- Minimum qualifying rhinoconjunctivitis symptom scores
Exclusion criteria
- History of asthma (asthma in childhood .
- A history of anaphylaxis to HDM allergen.
- Subjects with an FEV1 <80% of predicted.
- Subjects who cannot tolerate baseline challenge in the EEC.
- Subjects for whom administration of epinephrine is contra-indicated (e.g. subjects with acute or chronic symptomatic coronary heart disease or severe hypertension).
- A history of severe drug allergy, severe angioedema or anaphylactic reaction to food.
- A history of any significant disease or disorder (e.g. cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, neoplastic/malignant, psychiatric, major physical impairment).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Intradermal injection 1 x 11 administrations 4 weeks apart
|
Experimental: ToleroMune HDM Dose 1
|
Intradermal injection 1 x 11 administrations 4 weeks apart
|
Experimental: ToleroMune HDM Dose 2
|
Intradermal injection 1 x 11 administrations 4 weeks apart
|
Experimental: ToleroMune HDM Dose 3
|
Intradermal injection 1 x 11 administrations 4 weeks apart
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total Rhinoconjunctivitis Symptom Score
Time Frame: Up to 47 weeks
|
Up to 47 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Symptom scores for nasal and non-nasal symptoms
Time Frame: Up to 47 weeks
|
Up to 47 weeks
|
Total Rhinoconjunctivitis Symptom Score
Time Frame: Up to 19 weeks
|
Up to 19 weeks
|
Total Rhinoconjunctivitis Symptom Score
Time Frame: Up to 36 weeks
|
Up to 36 weeks
|
HDM specific IgA
Time Frame: Up to 53 weeks
|
Up to 53 weeks
|
HDM specific IgE
Time Frame: Up to 53 weeks
|
Up to 53 weeks
|
HDM specific IgG4
Time Frame: Up to 53 weeks
|
Up to 53 weeks
|
Adverse Events
Time Frame: Upto 53 weeks
|
Upto 53 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Deepen Patel, MD, CCFP, Cetero Research, San Antonio
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- TH002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rhinoconjunctivitis
-
ALK-Abelló A/SCompletedAllergic RhinoconjunctivitisGermany
-
ClinNovis GmbHCompletedRhinoconjunctivitis, AllergicGermany
-
BioTech Tools S.A.CompletedSeasonal Allergic RhinoconjunctivitisBelgium
-
University of ZurichCompleted
-
Roxall Medicina España S.ACompleted
-
Medical University of GrazRecruiting
-
Immunomic Therapeutics, Inc.Completed
-
University of ZurichCompletedAllergic RhinoconjunctivitisSwitzerland
-
ALK-Abelló A/SCompleted
-
ALK-Abelló A/SCompletedAllergic RhinoconjunctivitisSpain
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States